GSK and Sanofi delay the expected rollout of their COVID-19 vaccine until late 2021 because of an insufficient response in older people. The US has ordered 100 million doses.
- GlaxoSmithKline and Sanofi have delayed the potential rollout of their COVID-19 vaccine to the final months of 2021, after it didn’t show a strong enough response in older people.
- Interim results for human studies showed an “insufficient response in older adults,” the drugmakers said Friday — but they praised its effects in other age groups.
- The companies will repeat the early-stage studies with an improved formula in February, which will be supported by Operation Warp Speed, the White House’s vaccine effort.
- So far, the Pfizer-BioNTech vaccine is the only shot against COVID-19 that has been approved for use in the West, after being authorized in the UK and Canada earlier this month.
- In the US, the FDA is set to give its nod of approval at any time.
- Visit Business Insider’s homepage for more stories.
A COVID-19 vaccine being developed by two of the world’s biggest vaccine makers, GlaxoSmithKline and Sanofi, has been delayed after it didn’t show a strong enough response in older people.
GlaxoSmithKline and Sanofi are now expecting potential distribution of their shot in the final months of 2021. Initially, they had expected the vaccine to be available from mid-2021.
Interim results for early-phase human studies …continued .
[Source: Business Insider]